Among the more interesting clinical-stage biopharmaceutical companies for investors to consider is Brooklyn Immunotherapeutics (NYSEAMERICAN:BTX). I won’t claim that everyone needs to own BTX stock, ...

Today, investors in Brooklyn ImmunoTherapeutics (NYSEMKT:BTX) and BTX stock are seeing absolutely explosive gains. The stock is up approximately 50% at the time of writing on very heavy volume.

Because BioTime, Inc. (NYSEMKT:BTX) has witnessed a decline in interest from hedge fund managers, logic holds that there is a sect of fund managers that slashed their full holdings last quarter. It’s ...

BioTime, Inc. BTX was a big mover last session, as the company saw its shares rise almost 6%. The move came on solid volume too with far more shares changing hands than in a normal session. This ...